摘要
肾性贫血(renal anemia,RA)是血液透析(hemodialysis,HD)患者最常见的并发症,重组人促红细胞生成素(recombinant human erythropoietin,r-HuEPO)作为RA治疗的主要药物,临床总有效率高达90%以上,但仍有5%~10%的患者血红蛋白水平不能达标,这种对EPO的低反应是难治性RA的主要原因。过大剂量的r-HuEPO会加重不良反应的产生,增高患者病死率。中药可以通过调节机体免疫系统、抗炎等作用提高机体对r-HuEPO的敏感性,改善贫血,并减少r-HuEPO用量避免不良反应的产生。中药联合r-HuEPO可以达到1+1>2的效果,为临床RA治疗提供更为优异与安全的治疗方案。
Renal anemia(RA)is the most common complication of hemodialysis(HD)patients.Recombinant human erythropoietin(r-HuEPO),as the main drug for RA treatment,has a total clinical effective rate of more than 90%,but there are still 5%-10%of patients whose hemoglobin level cannot reach the standard.This low response to EPO is the main cause of refractory RA.Excessive doses of r-HuEPO will aggravate adverse reactions and increase patient mortality.Traditional Chinese medicine can improve the body's sensitivity to r-HuEPO,improve anemia,and reduce the amount of r-HuEPO to avoid adverse reactions by regulating the body's immune system,anti-inflammatory,etc..Chinese medicine combined with r-HuEPO can achieve the effect of 1+1>2,providing a more excellent and safe treatment plan for clinical RA treatment.
作者
王文静
赵春燕
孟双双
潘红梅
Wang Wenjing;Zhao Chunyan;Meng Shuangshuang(The Chengde Medical University,Chengde,Hebei067000;The Hebei University of Tiaditional Chinese Medicine,Shijiazhuang,Hebei050000)
出处
《基层医学论坛》
2022年第13期104-107,共4页
The Medical Forum
关键词
血液透析
贫血
促红细胞生成素低反应
中西医结合治疗
综述
Hemodialysis
Anemia Erythropoietin hyporesponsiveness
Integrated traditional Chinese and western medicine
Summary
